Comparing robot-assisted and conventional minimally invasive surgery for esophageal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial evaluates the effectiveness of robot-assisted minimally invasive esophagectomy (RAMIE) compared to conventional minimally invasive esophagectomy (MIE) for patients with resectable esophageal adenocarcinoma. It is a multicenter randomized controlled trial that aims to assess lymph node dissection, efficacy, risks, quality of life, and cost-effectiveness of both surgical approaches. Patients aged 18 to 90 with histologically confirmed adenocarcinoma will be randomly assigned to receive either RAMIE or MIE. The study is conducted in accordance with ethical guidelines and aims to improve surgical outcomes for esophageal cancer patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven adenocarcinoma of the intrathoracic esophagus and gastroesophageal junction (including Siewert I and II)
* Surgically resectable (T1-4a, N0-3, M0)
* Age ≥ 18 and ≤ 90 years
* European Clinical Oncology Group (ECOG) performance status 0,1 or 2
* Written informed consent

Exclusion Criteria:

* Esophageal squamous cell carcinoma
* Carcinoma of the cervical esophagus
* Carcinoma of the gastro-esophageal junction (GEJ) with the main part of the tumor in the gastric cardia (Siewert type III)
* Prior thoracic surgery at the right hemithorax or thoracic trauma

Where it's running

• University Medical Center Mainz
  Mainz, Germany Recruiting

Study contacts

• Principal investigator: Peter Grimminger, MD,PhD — JGU Medizin Mainz, dept. AVTC
• Study coordinator: Pieter Christiaan van der Sluis, MD,PhD
• Email: p.c.vandersluis-2@umcutrecht.nl
• Phone: +31628880709

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• Clonal Hematopoiesis Effects with Chemo and Radiation in Solid Cancers

  This study tests whether clonal hematopoiesis affects outcomes for adults with solid cancers who are receiving chemotherapy or radiation.

  Recruiting Dana-Farber Cancer Institute · Boston, Massachusetts · NCT07675967

• Testing ctDNA to detect minimal residual disease in GI cancers

  This study tests whether circulating tumor DNA can reveal minimal residual disease or early relapse in patients with esophageal, gastric, or pancreatic cancer who are receiving neoadjuvant or perioperative treatment.

  Recruiting Masaryk Memorial Cancer Institute · Brno · NCT07660627

• Upfront Chemoradiation With Consolidation Chemotherapy for Localized Esophageal Adenocarcinoma

  This study tests adding consolidative chemotherapy after chemoradiation to see if it better controls the cancer for people with localized esophageal adenocarcinoma who are candidates for chemoradiation.

  Recruiting Phase 2 Duke University · Durham, North Carolina · NCT07603375

• DISP-10 for advanced colorectal, gastric, and esophageal cancers

  This trial will test a one-time combination of an engineered adenovirus (DV-10) and BCMA-directed CAR T cells (ide-cel) in adults with advanced colorectal, gastric, or esophageal cancers.

  Recruiting at 6 sites Phase 1 Dispatch Biotherapeutics · Duarte, California and 6 other locations · NCT07544589

• Givastomig with nivolumab and chemotherapy for CLDN18.2-positive metastatic stomach or gastroesophageal junction cancer

  This study will see if adding givastomig to nivolumab plus standard chemotherapy helps adults with CLDN18.2- and PD-L1-positive metastatic stomach or gastroesophageal junction cancer live longer without their disease getting worse.

  Recruiting at 5 sites Phase 2 I-Mab Biopharma US Limited · Goodyear, Arizona and 5 other locations · NCT07432295

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.